Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating.
A new study published in The Korean Journal of Gastroenterology evaluated the efficacy of rifaximin in reducing bloating associated with functional gastrointestinal disorders (FGIDs). This study retrospectively assessed 63 patients who were treated with rifaximin (800-1,200 mg/day for 5 to 14 days) for FGIDs with bloating or gas-related symptoms between 2007 and 2013 at Seoul National University Bundang Hospital. The mean age of the patients was 56.8±14.2 years; 49.2% were fe
To continue reading this article
Continue reading your article with a Emedinexus account..